The future of PI3K research in cancer lies in a better understanding of the molecular mechanisms underlying PI3K pathway dysregulation and resistance to PI3K inhibitors. Combination therapies targeting multiple pathways simultaneously may provide a more effective approach to overcome resistance. Additionally, personalized medicine approaches that tailor PI3K-targeted therapies based on the specific genetic alterations in a patient’s tumor hold promise for improving outcomes in cancer treatment.
